The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways

被引:30
作者
Ruggiero, Carmen [1 ,2 ,3 ,4 ]
Doghman-Bouguerra, Mabrouka [1 ,2 ,3 ,4 ]
Ronco, Cyril [1 ,5 ]
Benhida, Rachid [1 ,5 ]
Rocchi, Stephane [1 ,6 ]
Lalli, Enzo [1 ,2 ,3 ,4 ]
机构
[1] Univ Cote Azur, F-06560 Valbonne, France
[2] CNRS UMR 7275, F-06560 Valbonne, France
[3] NEOGENEX CNRS Int Associated Lab, F-06560 Valbonne, France
[4] Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France
[5] ICN, Fac Sci, CNRS UMR 7272, 28 Ave Valrose, F-06108 Nice, France
[6] C3M, Equipe 12, INSERM U1065, F-06200 Nice, France
关键词
Adrenocortical carcinoma; ER stress; Steroidogenesis; ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS; MITOCHONDRIA; TARGET;
D O I
10.1016/j.mce.2018.02.010
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Many types of cancer cells present constitutively activated ER stress pathways because of their significant burden of misfolded proteins coded by mutated and rearranged genes. Further increase of ER stress by pharmacological intervention may shift the balance towards cell death and can be exploited therapeutically. Recent studies have shown that an important component in the mechanism of action of mitotane, the only approved drug for the medical treatment of adrenocortical carcinoma (ACC), is represented by activation of ER stress through inhibition of the SOAT1 enzyme and accumulation of toxic lipids. Here we show that HA15, a novel inhibitor of the essential ER chaperone GRP78/BiP, inhibits ACC H295R cell proliferation and steroidogenesis and is able to synergize with mitotane action. These results suggest that convergent activation of ER stress pathways by drugs acting via different mechanisms represents a valuable therapeutic option for ACC. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 64
页数:8
相关论文
共 31 条
  • [1] ATR-101 inhibits cholesterol efflux and cortisol secretion by ATP-binding cassette transporters, causing cytotoxic cholesterol accumulation in adrenocortical carcinoma cells
    Burns, Veronica Elizabeth
    Kerppola, Tom Klaus
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (19) : 3315 - 3332
  • [2] Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance
    Cerezo, Michael
    Lehraiki, Abdelali
    Millet, Antoine
    Rouaud, Florian
    Plaisant, Magali
    Jaune, Emilie
    Botton, Thomas
    Ronco, Cyril
    Abbe, Patricia
    Amdouni, Hella
    Passeron, Thierry
    Hofman, Veronique
    Mograbi, Baharia
    Dabert-Gay, Anne-Sophie
    Debayle, Delphine
    Alcor, Damien
    Rabhi, Nabil
    Annicotte, Jean-Sebastien
    Heliot, Laurent
    Gonzalez-Pisfil, Mariano
    Robert, Caroline
    Morera, Solange
    Vigouroux, Armelle
    Gual, Philippe
    Ali, Maruf M. U.
    Bertolotto, Corine
    Hofman, Paul
    Ballotti, Robert
    Benhida, Rachid
    Rocchi, Stephane
    [J]. CANCER CELL, 2016, 29 (06) : 805 - 819
  • [3] ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo
    Cheng, Yunhui
    Kerppola, Raili Emilia
    Kerppola, Tom Klaus
    [J]. ENDOCRINE-RELATED CANCER, 2016, 23 (04) : 1 - 19
  • [4] Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
    Chou, Ting-Chao
    [J]. CANCER RESEARCH, 2010, 70 (02) : 440 - 446
  • [5] Future directions in the diagnosis and medical treatment of adrenocortical carcinoma
    Creemers, S. G.
    Hofland, L. J.
    Korpershoek, E.
    Franssen, G. J. H.
    van Kemenade, F. J.
    de Herder, W. W.
    Feelders, R. A.
    [J]. ENDOCRINE-RELATED CANCER, 2016, 23 (01) : R43 - R69
  • [6] Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer
    Doghman, Mabrouka
    Karpova, Tatiana
    Rodrigues, Giovanna Assis
    Arhatte, Malika
    De Moura, Juliana
    Cavalli, Luciane R.
    Virolle, Virginie
    Barbry, Pascal
    Zambetti, Gerard P.
    Figueiredo, Bonald C.
    Heckert, Leslie L.
    Lalli, Enzo
    [J]. MOLECULAR ENDOCRINOLOGY, 2007, 21 (12) : 2968 - 2987
  • [7] FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria
    Doghman-Bouguerra, Mabrouka
    Granatiero, Veronica
    Sbiera, Silviu
    Sbiera, Iuliu
    Lacas-Gervais, Sandra
    Brau, Frederic
    Fassnacht, Martin
    Rizzuto, Rosario
    Lalli, Enzo
    [J]. EMBO REPORTS, 2016, 17 (09) : 1264 - 1280
  • [8] Adrenocortical Carcinoma
    Else, Tobias
    Kim, Alex C.
    Sabolch, Aaron
    Raymond, Victoria M.
    Kandathil, Asha
    Caoili, Elaine M.
    Jolly, Shruti
    Miller, Barbra S.
    Giordano, Thomas J.
    Hammer, Gary D.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (02) : 282 - 326
  • [9] Combination Chemotherapy in Advanced Adrenocortical Carcinoma
    Fassnacht, Martin
    Terzolo, Massimo
    Allolio, Bruno
    Baudin, Eric
    Haak, Harm
    Berruti, Alfredo
    Welin, Staffan
    Schade-Brittinger, Carmen
    Lacroix, Andre
    Jarzab, Barbara
    Sorbye, Halfdan
    Torpy, David J.
    Stepan, Vinzenz
    Schteingart, David E.
    Arlt, Wiebke
    Kroiss, Matthias
    Leboulleux, Sophie
    Sperone, Paola
    Sundin, Anders
    Hermsen, Ilse
    Hahner, Stefanie
    Willenberg, Holger S.
    Tabarin, Antoine
    Quinkler, Marcus
    de la Fouchardiere, Christelle
    Schlumberger, Martin
    Mantero, Franco
    Weismann, Dirk
    Beuschlein, Felix
    Gelderblom, Hans
    Wilmink, Hanneke
    Sender, Monica
    Edgerly, Maureen
    Kenn, Werner
    Fojo, Tito
    Muller, Hans-Helge
    Skogseid, Britt
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (23) : 2189 - 2197
  • [10] ACAT-selective and Nonselective DGAT1 Inhibition: Adrenocortical Effects-A Cross-species Comparison
    Floettmann, Jan Eike
    Buckett, Linda K.
    Turnbull, Andrew V.
    Smith, Tim
    Hallberg, Carina
    Birch, Alan
    Lees, David
    Jones, Huw B.
    [J]. TOXICOLOGIC PATHOLOGY, 2013, 41 (07) : 941 - 950